Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed exchanges that its subsidiary, Optival Health Solutions Private Limited, received a 21-day suspension order for the Drug License of one of its stores located at Shanti Nagar, Nagpur, Maharashtra. The order was issued by the Assistant Commissioner & Licensing Authority, Food & Drug Administration, Nagpur, on November 1, 2025, under Rule 65 of the Drugs and Cosmetics Act, 1940. The company has disclosed a potential revenue loss of approximately Rs 4.34 lakhs from this suspension. The order affects only a single store and is a routine regulatory compliance update under SEBI listing regulations.
The impact is negligible for shareholders — a 21-day suspension of a single store with a revenue loss of just Rs 4.34 lakhs is immaterial to Medplus's overall operations, given its large retail network. No material effect on stock price or financial performance is expected.